FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205506118> ?p ?o ?g. }

• W4205506118 endingPage "244" @default.
• W4205506118 startingPage "244" @default.
• W4205506118 abstract "244 Background: In pts with resectable gastric adenocarcinoma or OGA, radical surgery is the only curative option and perioperative chemotherapy seems worthless for those with MSI/dMMR tumors. Methods: We conducted phase II study evaluating the efficacy of neo-adjuvant nivolumab and ipilimumab followed by adjuvant nivolumab in pts with resectable MSI/dMMR, T2-T4 NxM0 tumors. Treatment consisted of nivolumab 240 mg every 2 weeks (6 infusions) and ipilimumab 1 mg/kg every 6 weeks (2 infusions), followed by radical surgery 5 weeks (±1 week) after last injection of nivolumab. Pts with Becker tumor regression grade (TRG) < 3 were treated with adjuvant nivolumab 480 mg every 4 weeks (9 infusions). The primary objective was pathological complete response (pCR) rate. Results: From 10/2019 to 06/2021, a total of 32 pts were enrolled (all had dMMR±MSI-H status; 16 with gastric cancer and 16 with OGA). The median age was 65.5 years (range, 40-80). Initial stage was: usT3Nx = 22, usT2Nx = 4, and usTxNx = 6 (not evaluable by ultrasound endoscopy). At data lock, 32 pts had terminated neo-adjuvant period and 27 (84%) completed all 6 neo-adjuvant cycles. 8 pts (32%) experienced G3/4 adverse events (AEs) during neo-adjuvant treatment. 29 pts underwent surgery; 2 refused surgery and had complete endoscopic response with tumor-free biopsies, 1 had surgery not performed in relation with a metastatic progression. The median delay between last injection and surgery was 35 days (extreme, 25-170). Overall surgical morbidity (54%, n = 14) was related to: anastomotic leakage = 4, pancreatitis = 2, pneumonia = 2, and other = 6. The incidence of post-operative mortality was 3.8% (n = 1) due to cardiovascular AE at post-operative day 3. All the 29 pts who underwent surgery had R0 resection: 17 (59%) had pCR (i.e., TRG 1a as per Becker grade, ypT0N0) and 4 (14%) had TRG 1b as per Beker grade (< 10% residual tumor per tumor bed). 1 pt had TRG 2 (10-50% of residual tumor) and 7 pts had TRG 3 (˃50% of residual tumor) as per Becker grade, per local pathological assessment (central pathological review is awaited). With a median follow-up of 10.9 months, 1 pt had metastatic relapse, 1 pt died without relapse and 30 pts were recurrence/progression-free. Conclusions: Neo-adjuvant therapy with nivolumab and ipilimumab is feasible and is associated with a high pCR rate in pts with MSI/dMMR resectable OGA. Data will be updated for the congress. Clinical trial information: NCT04006262." @default.
• W4205506118 created "2022-01-26" @default.
• W4205506118 creator A5002063921 @default.
• W4205506118 creator A5007652791 @default.
• W4205506118 creator A5010902289 @default.
• W4205506118 creator A5016699090 @default.
• W4205506118 creator A5020893157 @default.
• W4205506118 creator A5026512478 @default.
• W4205506118 creator A5035514936 @default.
• W4205506118 creator A5040688022 @default.
• W4205506118 creator A5040985815 @default.
• W4205506118 creator A5049661683 @default.
• W4205506118 creator A5053297306 @default.
• W4205506118 creator A5060536774 @default.
• W4205506118 creator A5062159596 @default.
• W4205506118 creator A5072953590 @default.
• W4205506118 creator A5074346281 @default.
• W4205506118 creator A5075053811 @default.
• W4205506118 creator A5079480540 @default.
• W4205506118 date "2022-02-01" @default.
• W4205506118 modified "2023-10-18" @default.
• W4205506118 title "Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study." @default.
• W4205506118 doi "https://doi.org/10.1200/jco.2022.40.4_suppl.244" @default.
• W4205506118 hasPublicationYear "2022" @default.
• W4205506118 type Work @default.
• W4205506118 citedByCount "35" @default.
• W4205506118 countsByYear W42055061182022 @default.
• W4205506118 countsByYear W42055061182023 @default.
• W4205506118 crossrefType "journal-article" @default.
• W4205506118 hasAuthorship W4205506118A5002063921 @default.
• W4205506118 hasAuthorship W4205506118A5007652791 @default.
• W4205506118 hasAuthorship W4205506118A5010902289 @default.
• W4205506118 hasAuthorship W4205506118A5016699090 @default.
• W4205506118 hasAuthorship W4205506118A5020893157 @default.
• W4205506118 hasAuthorship W4205506118A5026512478 @default.
• W4205506118 hasAuthorship W4205506118A5035514936 @default.
• W4205506118 hasAuthorship W4205506118A5040688022 @default.
• W4205506118 hasAuthorship W4205506118A5040985815 @default.
• W4205506118 hasAuthorship W4205506118A5049661683 @default.
• W4205506118 hasAuthorship W4205506118A5053297306 @default.
• W4205506118 hasAuthorship W4205506118A5060536774 @default.
• W4205506118 hasAuthorship W4205506118A5062159596 @default.
• W4205506118 hasAuthorship W4205506118A5072953590 @default.
• W4205506118 hasAuthorship W4205506118A5074346281 @default.
• W4205506118 hasAuthorship W4205506118A5075053811 @default.
• W4205506118 hasAuthorship W4205506118A5079480540 @default.
• W4205506118 hasConcept C121608353 @default.
• W4205506118 hasConcept C126322002 @default.
• W4205506118 hasConcept C141071460 @default.
• W4205506118 hasConcept C143998085 @default.
• W4205506118 hasConcept C2777701055 @default.
• W4205506118 hasConcept C2777863537 @default.
• W4205506118 hasConcept C2780030458 @default.
• W4205506118 hasConcept C2781182431 @default.
• W4205506118 hasConcept C2781433595 @default.
• W4205506118 hasConcept C31174226 @default.
• W4205506118 hasConcept C71924100 @default.
• W4205506118 hasConcept C90924648 @default.
• W4205506118 hasConceptScore W4205506118C121608353 @default.
• W4205506118 hasConceptScore W4205506118C126322002 @default.
• W4205506118 hasConceptScore W4205506118C141071460 @default.
• W4205506118 hasConceptScore W4205506118C143998085 @default.
• W4205506118 hasConceptScore W4205506118C2777701055 @default.
• W4205506118 hasConceptScore W4205506118C2777863537 @default.
• W4205506118 hasConceptScore W4205506118C2780030458 @default.
• W4205506118 hasConceptScore W4205506118C2781182431 @default.
• W4205506118 hasConceptScore W4205506118C2781433595 @default.
• W4205506118 hasConceptScore W4205506118C31174226 @default.
• W4205506118 hasConceptScore W4205506118C71924100 @default.
• W4205506118 hasConceptScore W4205506118C90924648 @default.
• W4205506118 hasIssue "4_suppl" @default.
• W4205506118 hasLocation W42055061181 @default.
• W4205506118 hasLocation W42055061182 @default.
• W4205506118 hasLocation W42055061183 @default.
• W4205506118 hasOpenAccess W4205506118 @default.
• W4205506118 hasPrimaryLocation W42055061181 @default.
• W4205506118 hasRelatedWork W2155654588 @default.
• W4205506118 hasRelatedWork W2752227448 @default.
• W4205506118 hasRelatedWork W2765163860 @default.
• W4205506118 hasRelatedWork W2780485172 @default.
• W4205506118 hasRelatedWork W2947988614 @default.
• W4205506118 hasRelatedWork W4226292283 @default.
• W4205506118 hasRelatedWork W4295817426 @default.
• W4205506118 hasRelatedWork W4295836810 @default.
• W4205506118 hasRelatedWork W4318473990 @default.
• W4205506118 hasRelatedWork W4319660705 @default.
• W4205506118 hasVolume "40" @default.
• W4205506118 isParatext "false" @default.
• W4205506118 isRetracted "false" @default.
• W4205506118 workType "article" @default.